Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy
- PDF / 805,831 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 50 Downloads / 151 Views
Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy Jiayi Zhang 1,2 & Zhaohu Yuan 1 & Weijie Zhong 3 & Yaming Wei 1,2 Accepted: 8 November 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Lymphoma is a heterogeneous malignancy and its incidence is increasing in the past decades all over the world. Although more than half of lymphoma patients achieve complete or partial remission from the standard first-line ABVD or R-CHOP based therapy, patients who fail to respond to these regimens will give rise to relapsed or refractory (R/R) lymphoma and may lead to a worse prognosis. Developing novel agents is important for R/R lymphoma. Based on the homing ability and being genetically modified easily, stem cells are usually used as vehicles in cell-based anti-tumor therapy, which can not only retain their own biological characteristics, but also make anti-tumor agents secrete constantly in tumor environment, to eventually kill the tumor cells more effectively. In this review, we will briefly introduce the properties of antibody therapy carried by stem cells, especially the hopes and hurdles of stem cell-mediated antibody secretion in the treatment of lymphoma. Keywords Lymphoma . Antibody . Mesenchymal stem cells . Gene therapy . Targeted therapy
Introduction Lymphoma, a malignant tumor originated from hematological system, can be divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) according to its different pathological features. The incidence of lymphoma has been increasing in the past decades. Worldwide, it is estimated that lymphoma accounts for appropriately 3.2% of all new cancer cases annually, of which HL and NHL represent about 12.5% and 87.5%, respectively [1]. With the wide application of standard front-line combination chemotherapy which include ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) therapy for HL, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) based therapy for NHL, and the secondline therapy like high-dose chemotherapy and autologous stem
* Yaming Wei [email protected] 1
Department of Blood Transfusion, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
2
Guangdong Engineering Research Center of Precise Transfusion, Guangzhou, Guangdong, China
3
Department of Geriatrics, Hematology & Oncology ward, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
cell transplantation(ASCT), the mortality rate of lymphoma remains stable globally [2, 3]. However, some patients cannot be cured effectively, which ultimately lead to relapsed or refractory (R/R) lymphoma. It is reported that there are still nearly 300,000 people die of lymphoma annually, of which NHL accounts for almost 90% of all new lymphoma deaths [1]. Fortunately, taking single-agent antibody and introducing antibodies into conventional chemotherapy have made a promising improvemen
Data Loading...
